Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 1028-1041

  Berenguer, Marina ^a   Schuppan, Detlef ^b,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antifibrotic; Biopsy; Cirrhosis; Collagen; Elastography; Fibrosis; HCV; Hepatic stellate cell; Interferon; Liver; Macrophage; NAFLD; Post transplant; Progression; Second hit; Serum marker; T cell; TGFbeta; Transplantation

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL NEURAL NETWORK; DISEASE COURSE; ELASTOGRAPHY; GENETIC PREDISPOSITION; HEPATITIS C; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; NATURAL KILLER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN BLOOD PRESSURE; PREDICTIVE VALUE; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTHROMBIN TIME; ULTRASOUND;

EID: 84876296995     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.12.014     Document Type: Note

References (160)

1. R.H. Wiesner, M. Sorrell, and F. Villamil Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C Liver transpl 9 2003 S1 S9
2. D. Samuel, X. Forns, M. Berenguer, C. Trautwein, A. Burroughs, and M. Rizzetto Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006) J Hepatol 45 2006 127 143
3. E.J. Gane, B.C. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, and P.T. Donaldson Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
4. M. Prieto, M. Berenguer, J.M. Rayón, J. Córdoba, L. Argüello, and D. Carrasco High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
5. R. Sreekumar, A. Gonzalez-Koch, Y. Maor-Kendler, K. Batts, L. Moreno-Luna, and J. Poterucha Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation Hepatology 32 2000 1125 1130
6. M. Berenguer, M. Prieto, F. San Juan, J.M. Rayón, F. Martinez, and D. Carrasco Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 2002 202 210
7. A. Sánchez-Fueyo, J.C. Restrepo, L. Quintó, M. Bruguera, L. Grande, and J.M. Sánchez-Tapias Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft Transplantation 73 2002 56 63
8. M.H. Wali, M. Heydtmann, R.F. Harrison, B.K. Gunson, and D.J. Mutimer Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4 Liver Transpl 9 2003 796 804
9. U.P. Neumann, T. Berg, M. Bahra, G. Puhl, O. Guckelberger, and J.M. Langrehr Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up Transplantation 77 2004 226 231
10. N. Yilmaz, M.L. Shiffman, R.T. Stravitz, R.K. Sterling, V.A. Luketic, and A.J. Sanyal A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975 983
11. L.S. Belli, A.K. Burroughs, P. Burra, A.B. Alberti, D. Samonakis, and C. Cammà Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study Liver Transpl 13 2007 733 740
12. T. Walter, J. Dumortier, O. Guillaud, V. Hervieu, J.Y. Scoazec, and O. Boillot Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center Liver Transpl 13 2007 294 301
13. J.C. Lai, E.C. Verna, R.S. Brown Jr., J.G. O'Leary, J.F. Trotter, and L.M. Forman Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men Hepatology 54 2011 418 424
14. G. Mells, and J. Neuberger Protocol liver allograft biopsies Transplantation 85 2008 1686 1692
15. M. Sebagh, D. Samuel, T.M. Antonini, A. Coilly, D. Degli Esposti, and B. Roche Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients J Hepatol 56 2012 840 847
16. S.C. Abraham, J.J. Poterucha, C.B. Rosen, A.J. Demetris, and A.M. Krasinskas Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests Am J Surg Pathol 32 2008 965 973
17. S.J. Pelletier, J.C. Iezzoni, T.D. Crabtree, Y.S. Hahn, R.G. Sawyer, and T.L. Pruett Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity Liver Transpl 6 2000 44 53
18. E.J. Gane The natural history of recurrent hepatitis C and what influences this Liver Transpl 14 2008 S36 S44
19. M. Wali, R.F. Harrison, P.J. Gow, and D. Mutimer Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 2002 248 252
20. M. Berenguer, L. Ferrell, J. Watson, M. Prieto, M. Kim, and M. Rayón HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684
21. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, and R. Neuhaus Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
22. R.J. Firpi, M.F. Abdelmalek, C. Soldevila-Pico, R. Cabrera, J.J. Shuster, and D. Theriaque One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection Liver Transpl 10 2004 1240 1247
23. N. Selzner, N. Girgrah, L. Lilly, M. Guindi, M. Selzner, and G. Therapondos The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age Liver Transpl 14 2008 1778 1786
24. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
25. J.F. Gallegos-Orozco, A. Yosephy, B. Noble, B.A. Aqel, T.J. Byrne, and E.J. Carey Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course Liver Transpl 15 2009 1872 1881
26. M. Berenguer, V. Aguilera, M. Prieto, D. Carrasco, M. Rayón, and F. San Juan Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 9 2003 1152 1158
27. P. Bacchetti, R.D. Boylan, N. Terrault, A. Monto, and M. Berenguer Non-Markov multistate modelling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplantation Int J Biostatistics 6 2010 Art 7
28. S. Ramírez, S. Pérez-Del-Pulgar, and X. Forns Virology and pathogenesis of hepatitis C virus recurrence Liver Transpl 14 2008 S27 S35
29. G.W. McCaughan, and A. Zekry Mechanisms of HCV reinfection and allograft damage after liver transplantation J Hepatol 40 2004 368 374
30. M. Guido, S. Fagiuoli, G. Tessari, P. Burra, G. Leandro, and P. Boccagni Histology predicts cirrhotic evolution of post transplant hepatitis C Gut 50 2002 697 700
31. Z. Meriden, K.A. Forde, T.L. Pasha, J.J. Hui, K.R. Reddy, and E.E. Furth Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection Clin Gastroenterol Hepatol 8 2010 289 296 296.e1-8
32. S.G. Hübscher What is the long-term outcome of the liver allograft? J Hepatol 55 2011 702 717
33. A.J. Demetris Evolution of hepatitis C virus in liver allografts Liver Transpl 15 2009 S35 S41
34. S.G. Hübscher Steatosis and fibrosis progression in patients with recurrent hepatitis C infection: complex interactions providing diagnostic and therapeutic challenges Liver Transpl 17 2011 1374 1379
35. J. Levitsky, M.I. Fiel, J.P. Norvell, E. Wang, K.D. Watt, and M.P. Curry Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon Gastroenterology 142 2012 1132 1139
36. N. Selzner, M. Guindi, E.L. Renner, and M. Berenguer Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients J Hepatol 55 2011 207 217
37. C.S. Wang, H.H. Ko, E.M. Yoshida, C.A. Marra, and K. Richardson Interferon-based combination therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis Am J Transplant 6 2006 1586 1599
38. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
39. E. Xirouchakis, C. Triantos, P. Manousou, A. Sigalas, V. Calvaruso, and A. Corbani Pegylated interferon and ribavirn in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective studies J Viral Hepatol 15 2008 699 709
40. B. Roche, M. Sebagh, M.L. Canfora, T. Antonini, A.M. Roque-Afonso, and V. Delvart Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis Liver Transpl 14 2008 1766 1777
41. J.A. Carrion, M. Navasa, M. Garcia-Retortillo, J.C. García-Pagan, G. Crespo, and M. Bruguera Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746 1756
42. F.P. Picciotto, G. Tritto, A.G. Lanza, L. Addario, M. De Luca, and G.G. Di Costanzo Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation J Hepatol 46 2007 459 465
43. M. Berenguer, V. Aguilera, M. Prieto, C. Ortiz, M. Rodríguez, and F. Gentili Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis Liver Transpl 15 2009 738 746
44. M. Berenguer, V. Aguilera, A. Rubín, C. Ortíz, M. Jimenez, and M. Prieto Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy J Hepatol 56 2012 1310 1316
45. A. Blasco, X. Forns, J.A. Carrión, J.C. García- Pagán, R. Gilabert, and A. Rimola Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
46. D.N. Samonakis, E. Cholongitas, U. Thalheimer, G. Kalambokis, A. Quaglia, and C.K. Triantos Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis Liver Transpl 13 2007 1305 1311
47. D.C. Rockey, S.H. Caldwell, Z.D. Goodman, R.C. Nelson, and A.D. Smith American Association for the Study of Liver Diseases. Liver biopsy Hepatology 49 2009 1017 1044
48. G. Germani, A.K. Burroughs, and A.P. Dhillon The relationship between liver disease stage and liver fibrosis: a tangled web Histopathology 57 2010 773 784
49. V. Calvaruso, A.K. Burroughs, R. Standish, P. Manousou, F. Grillo, and G. Leandro Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient Hepatology 49 2009 1236 1244
50. P. Manousou, A.P. Dhillon, G. Isgro, V. Calvaruso, T.V. Luong, and E. Tsochatzis Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation Liver Transpl 17 2011 178 188
51. M. Berenguer Non-invasive biomarkers of liver fibrosis in liver transplant patients with hepatitis C: can we avoid liver biopsies? Dig Liver Dis 41 2009 226 228
52. P. Toniutto, C. Fabris, D. Bitetto, E. Falleti, C. Avellini, and E. Rossi Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation J Gastroenterol Hepatol 22 2007 1904 1908
53. S. Benlloch, M. Berenguer, M. Prieto, J.M. Rayón, V. Aguilera, and J. Berenguer Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index Liver Transpl 11 2005 456 462
54. S. Benlloch, L. Heredia, C. Barquero, J.M. Rayón, R. Pina, and V. Aguilera Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients Liver Transpl 15 2009 1798 1807
55. J.S. Cross, T. Cross, D. Jothimani, M.A. Heneghan, and P.M. Harrison Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence Clin Transplant 25 2011 345 351
56. S. Beckebaum, S. Iacob, C.G. Klein, A. Dechêne, J. Varghese, and H.A. Baba Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients Transplantation 89 2010 983 993
57. S.M. Martínez, G. Crespo, M. Navasa, and X. Forns Noninvasive assessment of liver fibrosis Hepatology 53 2011 325 335
58. F. Piscaglia, A. Cucchetti, S. Benlloch, M. Vivarelli, J. Berenguer, and L. Bolondi Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors Eur J Gastroenterol Hepatol 12 2006 1255 1261
59. J.A. Carrión, G. Fernández-Varo, M. Bruguera, J.C. García-Pagán, J.C. García-Valdecasas, and S. Pérez-Del-Pulgar Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation Gastroenterology 138 2010 147 158.e1
60. D.G. Maluf, K.J. Archer, F. Villamil, R.T. Stravitz, and V. Mas Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression Expert Rev Gastroenterol Hepatol 4 2010 445 458
61. D. Micheloud, M. Salcedo, R. Bañares, D. Rincón, R. Lorente, and M.A. Muñoz-Fernández Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence Transpl Infect Dis 11 2009 183 188
62. S. Pungpapong, D.P. Nunes, M. Krishna, R. Nakhleh, K. Chambers, and M. Ghabril Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C Liver Transpl 14 2008 1294 1302
63. M.L. Berres, C. Trautwein, M. Schmeding, D. Eurich, F. Tacke, and M. Bahra Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection Hepatology 53 2011 596 603
64. J.A. Carrión, M. Navasa, J. Bosch, M. Bruguera, R. Gilabert, and X. Forns Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation Liver Transpl 12 2006 1791 1798
65. C. Rigamonti, M.F. Donato, M. Fraquelli, F. Agnelli, G. Ronchi, and G. Casazza Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation Gut 57 2008 821 827
66. F. Corradi, F. Piscaglia, S. Flori, A. D'Errico-Grigioni, F. Vasuri, and M.R. Tamé Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography Dig Liver Dis 41 2009 217 225
67. R. Masuzaki, N. Yamashiki, Y. Sugawara, H. Yoshida, R. Tateishi, and S. Tamura Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography Scand J Gastroenterol 44 2009 1115 1120
68. N. Harada, Y. Soejima, A. Taketomi, T. Yoshizumi, T. Ikegami, and Y. Yamashita Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation Transplantation 85 2008 69 74
69. C. Kamphues, K. Lotz, C. Röcken, T. Berg, D. Eurich, and J. Pratschke Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients Clin Transplant 24 2010 652 659
70. E. Cholongitas, E. Tsochatzis, J. Goulis, and A.K. Burroughs Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review Transpl Int 23 2010 861 870
71. C.O. Adebajo, J.A. Talwalkar, J.J. Poterucha, W.R. Kim, and M.R. Charlton Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis Liver Transpl 18 2012 323 331
72. J.A. Carrión, F. Torres, G. Crespo, R. Miquel, J.C. García-Valdecasas, and M. Navasa Liver stiffness identifies two different patterns of fibrosis Progression in patients with hepatitis C virus recurrence after liver transplantation Hepatology 51 2010 23 34
73. F. Piscaglia, A. Cucchetti, E. Terzi, and A. Gianstefani Validation of non-invasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation Liver Transpl 16 2010 1006 1007
74. M. Bolognesi, C. Quaglio, G. Bombonato, M. Guido, L. Cavalletto, and L. Chemello Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color Doppler Liver Transpl 14 2008 616 624
75. V.S. Lee, F.H. Miller, R.A. Omary, Y. Wang, D.R. Ganger, and E. Wang Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients Transplantation 92 2011 581 586
76. D. Schuppan, and N.H. Afdhal Lancet seminars: liver cirrhosis Lancet 371 2008 838 851
77. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669
78. K. Iwaisako, D.A. Brenner, and T. Kisseleva What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis J Gastroenterol Hepatol 27 2012 65 68
79. J.A. Dranoff, and R.G. Wells Portal fibroblasts: Underappreciated mediators of biliary fibrosis Hepatology 51 2010 1438 1444
80. Y. Popov, and D. Schuppan Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies Hepatology 50 2009 1294 1306
81. P.J. Murray, and T.A. Wynn Protective and pathogenic functions of macrophage subsets Nat Rev Immunol 11 2011 723 737
82. D. Schuppan, and M. Pinzani Anti-fibrotic therapy: lost in translation? J Hepatol 56 2012 S66 S74
83. D. Schuppan, A. Krebs, M. Bauer, and E.G. Hahn Hepatitis C and liver fibrosis Cell Death Differ 10 2003 S59 S67
84. A.V. Ivanov, O.A. Smirnova, O.N. Ivanova, O.V. Masalova, S.N. Kochetkov, and M.G. Isaguliants Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells PLoS One 6 2011 e24957
85. C.H. Hung, C.M. Lee, and S.N. Lu Hepatitis C virus-associated insulin resistance.pathogenic mechanisms and clinical implications Expert Rev Anti Infect Ther 9 2011 525 533
86. K. Koike, T. Tsutsumi, H. Yotsuyanagi, and K. Moriya Lipid metabolism and liver disease in hepatitis C viral infection Oncology 78 2010 24 30
87. H.E. Boudreau, S.U. Emerson, A. Korzeniowska, M.A. Jendrysik, and T.L. Leto Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress J Virol 83 2009 12934 12946
88. T. Wang, R.V. Campbell, M.K. Yi, S.M. Lemon, and S.A. Weinman Role of Hepatitis C virus core protein in viral-induced mitochondrial dysfunction J Viral Hepatol 17 2010 784 793
89. M. Korenaga, T. Wang, Y. Li, L.A. Showalter, T. Chan, and J. Sun Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production J Biol Chem 280 2005 37481 37488
90. A. Lonardo, L.E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C.P. Day Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 126 2004 586 597
91. L.E. Adinolfi, L. Restivo, R. Zampino, A. Lonardo, and P. Loria Metabolic alterations and chronic hepatitis C: treatment strategies Expert Opin Pharmacother 12 2011 2215 2234
92. M.Y. Sheikh, J. Choi, I. Qadri, J.E. Friedman, and A.J. Sanyal Hepatitis C virus infection: molecular pathways to metabolic syndrome Hepatology 47 2008 2127 2133
93. K. Safdar, and E.R. Schiff Alcohol and hepatitis C Semin Liver Dis 24 2004 305 315
94. A.K. Singal, and B.S. Anand Mechanisms of synergy between alcohol and hepatitis C virus J Clin Gastroenterol 41 2007 761 772
95. N. Rafiq, and Z.M. Younossi Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C Expert Rev Gastroenterol Hepatol 2 2008 207 215
96. C. Rigamonti, E. Mottaran, E. Reale, R. Rolla, V. Cipriani, and F. Capelli Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C Hepatology 38 2003 42 49
97. M. Vidali, G. Occhino, A. Ivaldi, C. Rigamonti, M. Sartori, and E. Albano Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C Am J Gastroenterol 103 2008 147 153
98. E.E. Powell, J.R. Jonsson, and A.D. Clouston Steatosis: co-factor in other liver diseases Hepatology 42 2005 5 13
99. M.J. Walsh, J.R. Jonsson, M.M. Richardson, G.M. Lipka, D.M. Purdie, and A.D. Clouston Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 Gut 55 2006 529 535
100. S.H. Ibrahim, R. Kohli, and G.J. Gores Mechanisms of lipotoxicity in NAFLD and clinical implications J Pediatr Gastroenterol Nutr 53 2011 131 140
101. K. Cusi Role of obesity and lipotoxicity in the development of non-alcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 142 2012 711 725
102. A. Schulze-Krebs, D. Preimel, Y. Popov, R. Bartenschlager, V. Lohmann, and M. Pinzani Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells Gastroenterology 129 2005 246 258
103. H. Taniguchi, N. Kato, M. Otsuka, T. Goto, H. Yoshida, and Y. Shiratori Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription J Med Virol 72 2004 52 59
104. A. Mazzocca, S.C. Sciammetta, V. Carloni, L. Cosmi, F. Annunziato, and T. Harada Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells J Biol Chem 280 2005 11329 11339
105. W. Lin, G. Wu, S. Li, E.M. Weinberg, K. Kumthip, and L.F. Peng HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB J Biol Chem 286 2011 2665 2674
106. W. Lin, E.M. Weinberg, A.W. Tai, L.F. Peng, M.A. Brockman, and K.A. Kim HIV increases HCV replication in a TGF-beta1-dependent manner Gastroenterology 134 2008 803 811
107. R. Bruno, S. Galastri, P. Sacchi, S. Cima, A. Caligiuri, and R. DeFranco Gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis Gut 59 2010 513 520
108. T.A. Wynn Cellular and molecular mechanisms of fibrosis J Pathol 214 2008 199 210
109. T.A. Wynn Integrating mechanisms of pulmonary fibrosis J Exp Med 208 2011 1339 1350
110. L. Barron, and T.A. Wynn Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages Am J Physiol Gastrointest Liver Physiol 300 2011 G723 G728
111. O. Park, W.I. Jeong, L. Wang, H. Wang, Z.X. Lian, and M.E. Gershwin Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride Hepatology 49 2009 1683 1694
112. R. Safadi, M. Ohta, C.E. Alvarez, M.I. Fiel, M. Bansal, and W.Z. Mehal Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes Gastroenterology 127 2004 870 882
113. N. Muhanna, L. Abu Tair, S. Doron, J. Amer, M. Azzeh, and M. Mahamid Amelioration of hepatic fibrosis by NK cell activation Gut 60 2011 90 98
114. F. Meng, K. Wang, T. Aoyama, S.I. Grivennikov, Y. Paik, and D. Scholten IL-17 signaling in inflammatory cells, Kupffer cells and Hepatic Stellate cells exacerbates liver fibrosis Gastroenterology 143 2012 765 776
115. S.M. Kamal, B. Turner, Q. He, J. Rasenack, L. Bianchi, and A. Al Tawil Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis Hepatology 43 2006 771 779
116. S.E. Davies, B.C. Portmann, J.G. O'Grady, P.M. Aldis, K. Chaggar, and G.J. Alexander Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis Hepatology 13 1991 150 157
117. K.N. Lowes, B.A. Brennan, G.C. Yeoh, and J.K. Olynyk Oval cell numbers in human chronic liver diseases are directly related to disease severity Am J Pathol 154 1999 537 541
118. A.D. Clouston, E.E. Powell, M.J. Walsh, M.M. Richardson, A.J. Demetris, and J.R. Jonsson Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis Hepatology 41 2005 809 818
119. M.M. Richardson, J.R. Jonsson, E.E. Powell, E.M. Brunt, B.A. Neuschwander-Tetri, and P.S. Bhathal Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction Gastroenterology 133 2007 80 90
120. T.M. Antonini, M. Sebagh, A.M. Roque-Afonso, E. Teicher, B. Roche, and R. Sobesky Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation Am J Transplant 11 2011 1686 1695
121. H. Huang, M.L. Shiffman, R.C. Cheung, T.J. Layden, S. Friedman, and O.T. Abar Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C Gastroenterology 130 2006 1679 1687
122. M. Marcolongo, B. Young, F. Dal Pero, G. Fattovich, L. Peraro, and M. Guido A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C Hepatology 50 2009 1038 1044
123. N.T. do O, D. Eurich, P. Schmitz, M. Schmeding, C. Heidenhain, and M. Bahra A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection Liver Transpl 18 2012 298 304
124. E. Seki, S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, and D.A. Brenner TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 13 2007 1324 1332
125. A.J. Paris, Z. Snapir, C.D. Christopherson, S.Y. Kwok, U.E. Lee, and Z. Ghiassi-Nejad A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis Hepatology 54 2011 2198 2207
126. A. Duarte-Rojo, M.G. Deneke, and M.R. Charlton IL28B polymorphism in hepatitis C and liver transplantation Liver Transpl 19 2013 49 58
127. F.X. López-Labrador, and M. Berenguer Genomic medicine reaches HCV-related liver transplantation: hopes and clinical and public health implications J Hepatol 55 2011 270 272
128. G.W. McCaughan, N.A. Shackel, and D.G. Bowen Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes? Liver transpl 17 2011 219 221
129. M.R. Charlton, A. Thompson, B.J. Veldt, K. Watt, H. Tillmann, and J.J. Poterucha Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection Hepatology 53 2011 317 324
130. C.M. Lange, D. Moradpour, A. Doehring, H.A. Lehr, B. Müllhaupt, and S. Bibert Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection J Hepatol 55 2011 322 327
131. M. Coto-Llerena, S. Pérez-Del-Pulgar, G. Crespo, J.A. Carrión, S.M. Martínez, and J.M. Sánchez-Tapias Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation Am J Transplant 11 2011 1051 1057
132. H. Rodriguez-Luna, A. Khatib, P. Sharma, G. De Petris, J.W. Williams, and J. Ortiz Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon a2b and ribavirin: an open-label series Transplantation 77 2004 190 194
133. G.W. Neff, M. Montalbano, C.B. O'Brien, S. Nishida, K. Safdar, and P.A. Bejarano Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy Transplantation 78 2004 1303 1307
134. A.S. Ross, A.K. Bhan, M. Pascual, M. Thiim, A.B. Cosimi, and R.T. Chung Pegylated interferon a-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C Clin Transplant 18 2004 166 173
135. J. Dumortier, J.Y. Scoazec, P. Chevallier, and O. Boillot Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 2004 669 674
136. P. Toniutto, C. Fabris, E. Fumo, L. Apollonio, M. Caldato, and C. Avellini Pegylated versus standard interferon-alfa in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy J Gastroenterol Hepatol 20 2005 577 582
137. M. Biselli, P. Andreone, A. Gramenzi, S. Lorenzini, E. Loggi, and F. Bonvicini Pegylated interferon plus ribavirin for recurrent epatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen Dig Liver Dis 38 2006 27 32
138. M. Berenguer, A. Palau, A. Fernandez, S. Benlloch, V. Aguilera, and M. Prieto Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C Liver transpl 12 2006 1067 1076
139. E. Oton, R. Barcena, J.M. Moreno-Planas, V. Cuervas-Mons, A. Moreno-Zamora, and C. Barrios Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin Am J Transplant 6 2006 2348 2355
140. S. Mukherjee, and E. Lyden Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series Hepatogastroenterology 53 2006 561 565
141. S. Mukherjee, and E. Lyden Impact of pegylated interferon a-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series Liver Int 26 2006 529 535
142. I. Fernandez, J.C. Meneu, F. Colina, I. Garcia, R. Munoz, and G. Castellano Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation Liver transpl 12 2006 1805 1812
143. U. Neumann, G. Puhl, M. Bahra, T. Berg, J.M. Langrehr, and R. Neuhaus Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin Transplantation 82 2006 43 47
144. M. Angelico, A. Petrolati, R. Lionetti, I. Lenci, P. Burra, and M.F. Donato A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C J Hepatol 46 2007 1009 1017
145. I.A. Hanouneh, C. Miller, F. Aucejo, R. Lopez, M.K. Quinn, and N.N. Zein Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy Liver Transpl 14 2008 53 58
146. M.F. Abdelmalek, R.J. Firpi, C. Soldevila-Pico, A.I. Reed, A.W. Hemming, and C. Liu Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C Liver Transpl 10 2004 199 207
147. T. Bizollon, P. Pradat, J.Y. Mabrut, M. Chevallier, M. Adham, and S. Radenne Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C Am J Transplant 5 2005 1909 1913
148. B.J. Veldt, J.J. Poterucha, K.D. Watt, R.H. Wiesner, J.E. Hay, and W.K. Kremers Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection Am J Transplant 8 2008 2426 2433
149. N. Selzner, E.L. Renner, and M. Selzner Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome Transplantation 88 2009 1214 1221
150. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayón, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
151. D. Mutimer Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation Liver Transpl 18 2012 Nov S47 S51
152. D.R. Nelson, Z. Tu, C. Soldevila-Pico, M. Abdelmalek, H. Zhu, and Y.L. Xu Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect Hepatology 38 2003 859 868
153. P.J. Pockros, L. Jeffers, N. Afdhal, Z.D. Goodman, D. Nelson, and R.G. Gish Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis Hepatology 45 2007 569 578
154. J. McHutchison, Z. Goodman, K. Patel, H. Makhlouf, M. Rodriguez-Torres, and M. Shiffman Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection Gastroenterology 138 2010 1365 1373
155. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, and E.C. Wright HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
156. R. Bataller, and D.A. Brenner Liver fibrosis J Clin Invest 115 2005 209 218
157. S.L. Friedman Evolving challenges in hepatic fibrosis Nat Rev Gastroenterol Hepatol 7 2010 425 436
158. J.A. Fallowfield Therapeutic targets in liver fibrosis Am J Physiol Gastrointest Liver Physiol 300 2011 G709 G715
159. K. Poelstra, and D. Schuppan Targeted therapy of liver fibrosis/cirrhosis and its complications J Hepatol 55 2011 726 728
160. I.N. Guha, R.P. Myers, K. Patel, and J.A. Talwalkar Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology 54 2011 1454 1462